Rocky Mountain Spotted Fever: A Physician's Challenge

Autor: Gordon E. Schutze, Samiya Razzaq
Rok vydání: 2005
Předmět:
Zdroj: Pediatrics in Review. 26:125-130
ISSN: 1526-3347
0191-9601
Popis: 1. Samiya Razzaq, MD* 2. Gordon E. Schutze, MD* 1. *University of Arkansas for Medical Sciences, School of Medicine, Department of Pediatrics, Arkansas Children’s Hospital, Little Rock, Ark After completing this article, readers should be able to: 1. Discuss the petechial rash and history of tick bite in relation to the diagnosis of Rocky Mountain spotted fever (RMSF). 2. Discuss the epidemiology of RMSF. 3. Know when, if ever, to withhold therapy for RMSF if clinically suspicious of the diagnosis. 4. Know the drug of choice for patients who have RMSF. RMSF is a tick-vectored disease that has been recognized in North America for more than a century. It remains a diagnostic challenge because of its varied clinical presentation and the overlap of signs and symptoms with other tick-borne diseases (eg, the Ehrlichia infections, human monocytic ehrlichiosis [HME]). Also known as tick fever, symptomatic presentations of RMSF are characterized by an acute febrile illness, headache, and rash. The causative agent is Rickettsia rickettsii , a gram-negative obligate intracellular bacterium. Because a delay in empiric antimicrobial therapy for RMSF can be fatal, clinicians need to be familiar with the presentation and management of this illness to avoid a poor outcome (Table 1). | | || Table 1. How to Avoid a Poor Outcome in the Diagnosis and Treatment of Rocky Mountain Spotted Fever RMSF was recognized initially in the northern Rocky Mountain and Pacific states. Today, RMSF has been reported in almost every state in the continental United States. From 1994 to 2003, the median number of cases reported to the Centers for Disease Control and Prevention (CDC) was 585/y (range, 365 to 1,104/y). Most cases were reported from the south Atlantic region (Delaware, Maryland, Washington …
Databáze: OpenAIRE